Home Tags RC48

Tag: RC48

Exclusive ADC-focused and Oncology deals in China Account for 41% of...

Over the past five years China has emerged as a major force in the research and development of innovative therapies for the treatment of...

RC118 Targeting Claudin 18.2 ADC Receives Two Orphan Drug Designations

RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

Chinese Regulator Conditionally Approves Disitamab Vedotin in Advanced or Metastatic Gastric...

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical Products Administration (NMPA; 国家药品监督管理局) of...

U.S. FDA Grants Breakthrough Therapy Designation for Disitamab Vedotin in Urothelial...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for disitamab vedotin (previously known as RC48), for the second-line treatment of...

Disitamab Vedotin Shows Clinically Meaningful Response and Survival Benefit in Heavily...

Data from a phase II study of disitamab vedotin (previously known as RC48) shows clinically meaningful results in the treatment of heavily pretreated patients...

IND for RemeGen’s Disitamab Vedotin Marks Important Milestone for the Company’s...

The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application allowing Yantai (Shandong Province; China) -based biopharmaceutical company RemeGen...
General views from the 2019 Annual Meeting of the American Society (ASCO), held May 31 - June 4, 2019. Courtesy © ASCO/Phil McCarten 2019.

RC48-ADC Demonstrates Clinically Meaningful Results in HER2+ Metastatic and Unresectable Urothelial...

Clinically meaningful topline results for a Phase II clinical trial of RC48-ADC were presented during the annual meeting of the American Society of Clinical...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers

Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...

X